Director Alessandra Cesano receives 27,000 RSUs at PUMA Biotech (PBYI)

Rhea-AI Filing Summary

Cesano Alessandra reported acquisition or exercise transactions in this Form 4 filing.

PUMA Biotechnology director Alessandra Cesano reported an equity award of 27,000 shares of Common Stock on June 11, 2026. The award is in the form of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to her continued service with the company.

Following this grant, Cesano directly holds 68,850 shares. This is a compensation-related grant, not an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cesano Alessandra

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	27,000	$0.00	--

Holdings After Transaction: Common Stock — 68,850 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 27,000 shares Post-transaction holdings: 68,850 shares Grant price: $0.0000 per share +1 more

4 metrics

RSU grant size 27,000 shares Restricted Stock Units granted to director on June 11, 2026

Post-transaction holdings 68,850 shares Total direct Common Stock holdings after grant

Grant price $0.0000 per share Indicates a compensation grant, not an open-market purchase

Vesting condition 1 year or next annual meeting RSUs vest on earlier of one-year anniversary or next annual shareholder meeting

Key Terms

Restricted Stock Units, annual shareholder meeting, transaction code A, continued service

4 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual shareholder meeting financial

"the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

transaction code A regulatory

"transaction_code_description: Grant, award, or other acquisition"

continued service financial

"subject to the Reporting Person's continued service with the Issuer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cesano Alessandra

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		27,000	A	$0(1)	68,850	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

	/s/ Gordon Esplin as attorney-in-fact for Alessandra Cesano	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PUMA Biotechnology (PBYI) director Alessandra Cesano report in this Form 4?

Director Alessandra Cesano reported an equity grant of 27,000 shares of PUMA Biotechnology Common Stock. The award is structured as Restricted Stock Units that were granted as compensation, rather than purchased in the open market, and increased her direct holdings to 68,850 shares.

Is the 27,000 share award to PUMA Biotechnology (PBYI) director an open-market purchase?

No, the 27,000 shares reflect a grant of Restricted Stock Units, not an open-market purchase. The Form 4 classifies the transaction under code A, meaning a grant, award, or similar acquisition as part of director compensation rather than a discretionary share purchase.

When do the Restricted Stock Units granted to PBYI director Alessandra Cesano vest?

The Restricted Stock Units vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholder meeting. Vesting is conditioned on Cesano’s continued service with PUMA Biotechnology through that applicable vesting date.

How many PUMA Biotechnology shares does Alessandra Cesano hold after this Form 4 transaction?

After the grant, Alessandra Cesano directly holds 68,850 shares of PUMA Biotechnology Common Stock. This total includes the newly awarded 27,000 Restricted Stock Units reported in the filing, reflecting her updated direct ownership position as of the transaction date.

What does transaction code A mean in the PUMA Biotechnology (PBYI) Form 4 filing?

Transaction code A in this filing indicates a grant, award, or other acquisition of equity, not a market trade. Here it refers to 27,000 Restricted Stock Units granted to director Alessandra Cesano as part of her compensation from PUMA Biotechnology.